Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Enquête sur la chimiothérapie de la vessie au lieu de la chirurgie pour le cancer de la vessie à faible risque (CALIBER)

4 novembre 2026 mis à jour par: Institute of Cancer Research, United Kingdom

CALIBER - Une étude de faisabilité randomisée de phase II sur la chimiorésection et la prise en charge chirurgicale du cancer de la vessie non invasif musculaire à faible risque

Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.

Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.

Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.

Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.

Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.

Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.

All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.

Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.

Type d'étude

Interventionnel

Inscription (Réel)

82

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • London, Royaume-Uni, NW1 2BU
        • University College Hospital
      • Manchester, Royaume-Uni, M23 9LT
        • Wythenshawe Hospital
      • Manchester, Royaume-Uni, M20 2LR
        • Withington Hospital
    • Cheshire
      • Macclesfield, Cheshire, Royaume-Uni, SK10 3BL
        • Macclesfield District General Hospital
    • Cleveland
      • Middlesbrough, Cleveland, Royaume-Uni, TS4 3BW
        • James Cook University Hospital
    • Cumbria
      • Whitehaven, Cumbria, Royaume-Uni, CA28 8JG
        • West Cumberland Hospital
    • Devon
      • Exeter, Devon, Royaume-Uni, EX2 5DW
        • Royal Devon and Exeter Hospital
      • Plymouth, Devon, Royaume-Uni, PL6 8DH
        • Derriford Hospital
    • Dorset
      • Bournemouth, Dorset, Royaume-Uni, BH7 7DW
        • Royal Bournemouth Hospital
      • Dorchester, Dorset, Royaume-Uni, DT1 2JY
        • Dorset County Hospital
    • England
      • Carlisle, England, Royaume-Uni, CA2 7HY
        • Cumberland Infirmary
    • Essex
      • Chelmsford, Essex, Royaume-Uni, CM1 5ET
        • Broomfield Hospital
      • Harlow, Essex, Royaume-Uni, CM20 1QX
        • Princess Alexandra Hospital
    • Gloucestershire
      • Cheltenham, Gloucestershire, Royaume-Uni, GL53 7AN
        • Cheltenham General Hospital
      • Gloucester, Gloucestershire, Royaume-Uni, GL1 3NN
        • Gloucestershire Royal Hospital
    • Greater Manchester
      • Manchester, Greater Manchester, Royaume-Uni, OL1 2JH
        • Royal Oldham Hospital
    • Hampshire
      • Basingstoke, Hampshire, Royaume-Uni, RG24 9NA
        • Basingstoke and North Hampshire Hospital
      • Southampton, Hampshire, Royaume-Uni, SO16 6YD
        • Southampton General Hospital
    • Herefordshire
      • Hereford, Herefordshire, Royaume-Uni, HR1 2ER
        • Hereford County Hospital
    • Kent
      • Dartford, Kent, Royaume-Uni, DA2 8DA
        • Darent Valley Hospital
      • Gillingham, Kent, Royaume-Uni, ME7 5NY
        • Medway Maritime Hospital
    • Lancashire
      • Preston, Lancashire, Royaume-Uni, PR2 9HT
        • Royal Preston Hospital
    • Leicestershire
      • Leicester, Leicestershire, Royaume-Uni, LE5 4PW
        • Leicester General Hospital
    • Middlesex
      • Harrow, Middlesex, Royaume-Uni, HA1 3UJ
        • Northwick Park Hospital
    • Oxfordshire
      • Headington, Oxfordshire, Royaume-Uni, OX3 7LE
        • Churchill Hospital
    • South Yorkshire
      • Sheffield, South Yorkshire, Royaume-Uni, S10 2JF
        • Royal Hallamshire Hospital
    • Suffolk
      • Ipswich, Suffolk, Royaume-Uni, IP4 5PD
        • Ipswich Hospital
    • Surrey
      • Croydon, Surrey, Royaume-Uni, CR7 7YE
        • Croydon University Hospital
      • Guildford, Surrey, Royaume-Uni, GU2 7XX
        • Royal Surrey County Hospital
    • Tyne and Wear
      • Newcastle upon Tyne, Tyne and Wear, Royaume-Uni, NE7 7DN
        • Freeman Hospital
    • West Midlands
      • Wolverhampton, West Midlands, Royaume-Uni, WV10 0QP
        • New Cross Hospital
    • West Sussex
      • Chichester, West Sussex, Royaume-Uni, PO19 6SE
        • St Richard's Hospital
      • Worthing, West Sussex, Royaume-Uni, BN11 2DH
        • Worthing Hospital
    • West Yorkshire
      • Wakefield, West Yorkshire, Royaume-Uni, WF1 4DG
        • Pinderfields General Hospital
    • Worcestershire
      • Kidderminster, Worcestershire, Royaume-Uni, DY11 6RJ
        • Kidderminster Hospital
      • Redditch, Worcestershire, Royaume-Uni, B98 7UB
        • Alexandra Hospital
      • Worcester, Worcestershire, Royaume-Uni, WR5 1DD
        • Worcester Royal Hospital
    • Yorkshire
      • Leeds, Yorkshire, Royaume-Uni, LS9 7TF
        • St James's University Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

16 ans et plus (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Written informed consent
  • NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
  • Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
  • Aged 16 or over
  • Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
  • Negative pregnancy test for women of child-bearing potential

Exclusion Criteria:

  • Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
  • Any history of histologically confirmed non-TCC bladder cancer
  • Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
  • Any prior treatment of the trial entry recurrence (including biopsy)
  • Previous MMC chemotherapy other than a single instillation at diagnostic surgery
  • Known allergy to MMC
  • Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
  • Known or suspected reduced bladder capacity (<100ml)
  • Significant bleeding disorder
  • Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
  • Active or intractable urinary tract infection
  • Urethral stricture or anything impeding the insertion of a catheter
  • Large narrow neck diverticula
  • Significant urinary incontinence
  • Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
  • Unable or unwilling to comply with study procedures or follow up schedule

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Chemoresection

4 once weekly outpatient intravesical instillations 40mg Mitomycin C

Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.

Autres noms:
  • CMM
Autre: Surgical Management

Surgical management according to local practice

Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Complete response rate with chemoresection
Délai: 3 months

Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response.

3 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Treatment compliance in chemoresection group
Délai: Duration of treatment (3 weeks)

Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant.

Duration of treatment (3 weeks)
Salvage surgery rates
Délai: 3 years

Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups

3 years
Progression-free survival
Délai: 3 years

Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause.

3 years
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
Délai: up to 12 months

Measuring side effects of both treatments using clinician reported toxicity scales

up to 12 months
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
Délai: up to 12 months

Assessing side effects and impact of both treatments on patient reported quality of life.

up to 12 months
Health service utilisation
Délai: up to 12 months

Assessed using prospective data collection of health resource usage.

up to 12 months
Recurrence free interval
Délai: up to 12 months

Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months

up to 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Hugh Mostafid, Royal Surrey County Hospital NHS Foundation Trust

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 octobre 2014

Achèvement primaire (Réel)

1 janvier 2018

Achèvement de l'étude (Réel)

21 février 2022

Dates d'inscription aux études

Première soumission

19 février 2014

Première soumission répondant aux critères de contrôle qualité

21 février 2014

Première publication (Estimé)

25 février 2014

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner